Myers – Talk Bio

BMS Breaks Clinical Losing Streak with Positive Phase 3 Myeloma Readout for Iberdomide

1 month ago talkbio0Tagged CELMoD, Clinical Trials, EXCALIBER-RRMM, iberdomide, Minimal Residual Disease Negativity, Multiple Myeloma, Myers, Phase 3, Progression-Free Survival, Protein Degradation, Metabolic, Relapsing course, squibb, Unresponsive to Treatment

Bristol Myers Squibb; iberdomide; multiple myeloma; clinical trial; EXCALIBER-RRMM; minimal residual disease negativity; CELMoD; protein degradation; progression-free survival; phase 3; relapsed or refractory

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

1 month ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

1 month ago talkbio0Tagged AB-2100, ArsenalBio, Cell Therapy, Clinical Trials, layoffs, Myers, restructuring, Squibb partnership, Staff

ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership

Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey

1 month ago talkbio0Tagged Drug Industry, layoffs, Myers, Nordisk, Ozempic, restructuring, Wegovy

Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

1 month ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

2 months ago talkbio0Tagged BioNTech, BNT327, Burning Mouth Syndrome, Myers, Overall response rate, PD-L1, PD-L1xVEGF, Pharmacotherapy, pumitamig, Small cell carcinoma of lung, squibb, Vascular Endothelial Growth Factor A

BioNTech; Bristol Myers Squibb; BMS; PD-L1xVEGF bispecific; BNT327; pumitamig; small cell lung cancer; SCLC; phase 2 trial; phase 3 dose; overall response rate; VEGF-A; PD-L1; chemotherapy

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

3 months ago talkbio0Tagged Afimetoran, Autoimmune Diseases, BMS-986322, Clinical Development, Immunology, Investments, Myers, squibb

Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

3 months ago talkbio0Tagged Anticoagulants, blood thinner, Direct-to-Consumer, Eliquis, Myers, online program, Pfizer, squibb

Bristol Myers Squibb; Pfizer; Eliquis; direct-to-consumer; discount; online program; Eliquis 360 Support; anticoagulant; blood thinner; patient access

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

4 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

5 months ago talkbio0Tagged Big Pharma, Chris Shibutani, Corporate, external partnerships, Goldman Sachs, Long-Term Strategy, Myers, squibb

Bristol Myers Squibb; Chris Shibutani; Goldman Sachs; Chief Strategy Officer; long-term strategy; biotech analyst; Big Pharma; external partnerships; corporate strategy